SCHEMBL888227

SCHEMBL888227

CC(OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1OP(=O)(O)OP(=O)(O)OP(=O)(O)O)c1ccc(C#CCN)cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
P2RX3 P56373 5/20 0.40
P2RX1 P51575 4/20 0.40
P2RX2 Q9UBL9 4/20 0.40
P2RX4 Q99571 4/20 0.40
ENPP1 P22413 2/20 0.40
P2RY1 P47900 1/20 0.40
RNASEL Q05823 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
P2RY12 Q9H244 1/20 0.38
P2RY2 P41231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140777 0.88 POLB (0.47) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL888084 0.88 POLB (0.47) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL4430328 0.80 POLB (0.48) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL887961 0.79 ENPP1 (0.43) POLBENPP1P2RY1
SCHEMBL16541281 0.78 POLB (0.44) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL889600 0.78 POLB (0.44) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL12570178 0.78 POLB (0.44) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL18044128 0.78 POLB (0.44) POLBP2RX3P2RX1P2RX2P2RX4
SCHEMBL16541288 0.77 POLB (0.43) POLBP2RX3P2RX1P2RX4ENPP1
SCHEMBL16541289 0.77 POLB (0.43) POLBP2RX3P2RX1P2RX4ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110287427-A1 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2011-11-24 US disclosed
US-7964352-B2 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2011-06-21 US disclosed
US-7897737-B2 Polymorphic identification; fluorescent dyes LASERGEN, INC. (US) 2011-03-01 US disclosed
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing AGILENT TECHNOLOGIES, INC. 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing UNG, DCLRE1B, NT5C3B POLB 28/4885P2RX3 1152/4885P2RX1 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.